Exploiting the WNT Signaling Pathway for Clinical Purposes

Mark L. Johnson, Robert R. Recker

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Purpose of Review: The goal of this paper is to evaluate critically the literature published over the past 3 years regarding the Wnt signaling pathway. The Wnt pathway was found to be involved in bone biology in 2001–2002 with the discovery of a (G171V) mutation in the lipoprotein receptor-related protein 5 (LRP5) that resulted in high bone mass and another mutation that completely inactivated Lrp5 function and resulted in osteoporosis pseudoglioma syndrome (OPPG). The molecular biology has been complex, and very interesting. It has provided many opportunities for exploitation to develop new clinical treatments, particularly for osteoporosis. More clinical possibilities include: treatments for fracture healing, corticosteroid osteoporosis, osteogenesis imperfecta, and others. In addition, we wish to provide historical information coming from distant publications (~350 years ago) regarding bone biology that have been confirmed by study of Wnt signaling. Recent Findings: A recent finding is the development of an antibody to sclerostin that is under study as a treatment for osteoporosis. Summary: Development of treatments for other forms of osteoporosis, such as corticosteroid osteoporosis, is also underway. The full range of the applications of the work is not yet been achieved.

Original languageEnglish (US)
Pages (from-to)153-161
Number of pages9
JournalCurrent Osteoporosis Reports
Volume15
Issue number3
DOIs
StatePublished - Jun 1 2017

Fingerprint

Critical Pathways
Osteoporosis
Wnt Signaling Pathway
Bone and Bones
Low Density Lipoprotein Receptor-Related Protein-5
Adrenal Cortex Hormones
Osteogenesis Imperfecta
Mutation
Fracture Healing
Publications
Molecular Biology
Antibodies

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism

Cite this

Exploiting the WNT Signaling Pathway for Clinical Purposes. / Johnson, Mark L.; Recker, Robert R.

In: Current Osteoporosis Reports, Vol. 15, No. 3, 01.06.2017, p. 153-161.

Research output: Contribution to journalReview article

@article{a6515addf90945588021f500b3ea9c64,
title = "Exploiting the WNT Signaling Pathway for Clinical Purposes",
abstract = "Purpose of Review: The goal of this paper is to evaluate critically the literature published over the past 3 years regarding the Wnt signaling pathway. The Wnt pathway was found to be involved in bone biology in 2001–2002 with the discovery of a (G171V) mutation in the lipoprotein receptor-related protein 5 (LRP5) that resulted in high bone mass and another mutation that completely inactivated Lrp5 function and resulted in osteoporosis pseudoglioma syndrome (OPPG). The molecular biology has been complex, and very interesting. It has provided many opportunities for exploitation to develop new clinical treatments, particularly for osteoporosis. More clinical possibilities include: treatments for fracture healing, corticosteroid osteoporosis, osteogenesis imperfecta, and others. In addition, we wish to provide historical information coming from distant publications (~350 years ago) regarding bone biology that have been confirmed by study of Wnt signaling. Recent Findings: A recent finding is the development of an antibody to sclerostin that is under study as a treatment for osteoporosis. Summary: Development of treatments for other forms of osteoporosis, such as corticosteroid osteoporosis, is also underway. The full range of the applications of the work is not yet been achieved.",
author = "Johnson, {Mark L.} and Recker, {Robert R.}",
year = "2017",
month = "6",
day = "1",
doi = "10.1007/s11914-017-0357-0",
language = "English (US)",
volume = "15",
pages = "153--161",
journal = "Curr Osteoporos Rep",
issn = "1544-1873",
publisher = "Current Science, Inc.",
number = "3",

}

TY - JOUR

T1 - Exploiting the WNT Signaling Pathway for Clinical Purposes

AU - Johnson, Mark L.

AU - Recker, Robert R.

PY - 2017/6/1

Y1 - 2017/6/1

N2 - Purpose of Review: The goal of this paper is to evaluate critically the literature published over the past 3 years regarding the Wnt signaling pathway. The Wnt pathway was found to be involved in bone biology in 2001–2002 with the discovery of a (G171V) mutation in the lipoprotein receptor-related protein 5 (LRP5) that resulted in high bone mass and another mutation that completely inactivated Lrp5 function and resulted in osteoporosis pseudoglioma syndrome (OPPG). The molecular biology has been complex, and very interesting. It has provided many opportunities for exploitation to develop new clinical treatments, particularly for osteoporosis. More clinical possibilities include: treatments for fracture healing, corticosteroid osteoporosis, osteogenesis imperfecta, and others. In addition, we wish to provide historical information coming from distant publications (~350 years ago) regarding bone biology that have been confirmed by study of Wnt signaling. Recent Findings: A recent finding is the development of an antibody to sclerostin that is under study as a treatment for osteoporosis. Summary: Development of treatments for other forms of osteoporosis, such as corticosteroid osteoporosis, is also underway. The full range of the applications of the work is not yet been achieved.

AB - Purpose of Review: The goal of this paper is to evaluate critically the literature published over the past 3 years regarding the Wnt signaling pathway. The Wnt pathway was found to be involved in bone biology in 2001–2002 with the discovery of a (G171V) mutation in the lipoprotein receptor-related protein 5 (LRP5) that resulted in high bone mass and another mutation that completely inactivated Lrp5 function and resulted in osteoporosis pseudoglioma syndrome (OPPG). The molecular biology has been complex, and very interesting. It has provided many opportunities for exploitation to develop new clinical treatments, particularly for osteoporosis. More clinical possibilities include: treatments for fracture healing, corticosteroid osteoporosis, osteogenesis imperfecta, and others. In addition, we wish to provide historical information coming from distant publications (~350 years ago) regarding bone biology that have been confirmed by study of Wnt signaling. Recent Findings: A recent finding is the development of an antibody to sclerostin that is under study as a treatment for osteoporosis. Summary: Development of treatments for other forms of osteoporosis, such as corticosteroid osteoporosis, is also underway. The full range of the applications of the work is not yet been achieved.

UR - http://www.scopus.com/inward/record.url?scp=85018798722&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018798722&partnerID=8YFLogxK

U2 - 10.1007/s11914-017-0357-0

DO - 10.1007/s11914-017-0357-0

M3 - Review article

VL - 15

SP - 153

EP - 161

JO - Curr Osteoporos Rep

JF - Curr Osteoporos Rep

SN - 1544-1873

IS - 3

ER -